Executive Summary
This digest covers a single Form 4-type insider transaction filing from Elevance Health, Inc. (an S&P 500 managed care/healthcare provider within scope). The only enriched event is a series of sales by EVP & CFO Kaye Mark totaling 2,343 shares at roughly $441 (~$1.03M), with 13 transactions reported and 19,919 shares retained afterward.
Executed prices clustered between $434 and $441, with individual lots of 400, 321 and 1,660 shares. No period-over-period financial comparisons, guidance, capital allocation changes, M&A, or scheduled events were supplied in the enriched data, so portfolio-level trend analysis is not possible from this single filing. The filing's sentiment is classified negative with 7/10 materiality, which reflects the insider selling rather than any fundamental deterioration. Investors should treat this as a limited-information signal and look for the company's periodic financial filings and guidance to contextualize it.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Filing types in this digest: Form 4
Tracking the trend? Catch up on the prior S&P 500 Healthcare Sector SEC Filings digest from October 22, 2026.
Investment Signals (1)
- Elevance Health ↓ (BEARISH)▲
EVP & CFO Kaye Mark sold 2,343 shares at ~$441.34 (~$1.03M) across 13 reported transactions, retaining 19,919 shares; insider selling by the CFO is a modest caution flag in the absence of offsetting insider buying
Risk Flags (1)
- Elevance Health/Insider Selling↓ [MEDIUM RISK]▼
CFO Kaye Mark disposed of 2,343 shares (~$1.03M) over multiple lots priced $434-$441, with 13 transactions reported; the sale is a negative sentiment marker, though the enriched data does not indicate whether it is a planned 10b5-1 sale or discretionary, and no pledge or holding-change context was provided
Sector Themes (1)
- Insider Selling Among Large-Cap Managed Care Executives◆
The single in-scope filing shows routine executive sell-downs at prices near $440; with only one company in this digest, no cross-sector pattern can be confirmed, and the theme should be revisited once additional S&P 500 healthcare filings are added to the stream.
Watch List (1)
-
Monitor for further Form 4 filings from the CFO or other C-suite executives to determine whether the sell-down is a continuing pattern or a one-time event; the enriched data gave no scheduled earnings or AGM date for this window
Filing Analyses
(1)
23-10-2026
EVP & CFO Kaye Mark sold 2,343 Common Stock at $441.34 (~$1.03M). 13 transactions reported in total. Kaye Mark holds 19,919 shares after the transaction.
- · EVP & CFO Kaye Mark sold 400 Common Stock at $434.00 (~$174K)
- · EVP & CFO Kaye Mark sold 321 Common Stock at $435.25 (~$140K)
- · EVP & CFO Kaye Mark sold 1,660 Common Stock at $436.20 (~$724K)
- · EVP & CFO Kaye Mark sold 560 Common Stock at $437.07 (~$245K)
- · EVP & CFO Kaye Mark sold 240 Common Stock at $438.22 (~$105K)
- · EVP & CFO Kaye Mark sold 1,160 Common Stock at $439.25 (~$510K)
- · EVP & CFO Kaye Mark sold 1,720 Common Stock at $440.44 (~$758K)
- · EVP & CFO Kaye Mark sold 2,343 Common Stock at $441.34 (~$1.03M)
Get daily alerts with 1 investment signals, 1 risk alerts and full AI analysis of all 1 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: S&P 500 Healthcare Sector SEC Filings
🇺🇸 More from United States
View all →October 23, 2026
US Pre-Market SEC Filings Roundup — October 23, 2026
US Pre-Market SEC Filings Roundup
October 23, 2026
US Merger & Acquisition SEC Filings — October 23, 2026
US Merger & Acquisition SEC Filings
October 23, 2026
USA Insider Trading Pulse — October 23, 2026
USA Insider Trading Pulse
October 23, 2026
US Corporate Board Director Changes SEC Filings — October 23, 2026
US Corporate Board Director Changes SEC Filings